52 completed, 28 unknown, 24 recruiting, 14 active not recruiting. 62 Phase 2, 58 Phase 1, 33 Phase 3, 3 Not applicable.
Follow Shanghai Junshi Bioscience Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC) JS212 in combination with JS207, JS212 monotherapy, JS212 in combination with JS001 - Triple-negative Breast Cancer | Phase 2 | Not yet recruiting | Shanghai Junshi Bioscience Co., Ltd. | 184 | 2026-10-15 | 2026-10-15 |
| JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer JS207, JS007, Toripalimab - Hepatocellular Carcinoma | Phase 3 | Not yet recruiting | Shanghai Junshi Bioscience Co., Ltd. | 560 | 2026-10-08 | 2026-09-16 |
| A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma JS203 in combination with gemcitabine and oxaliplatin, Rituximab in combination with gemcitabine and oxaliplatin - Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 282 | 2026-10-08 | 2026-10-14 |
| Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC Toripalimab, Sacituzumab Tirumotecan (SKB264) - Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Shaodong Hong | 30 | 2026-10-01 | 2026-09-15 |
| Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Cancer Propranolol Hydrochloride, Toripalimab, Chemotherapy - Resectable Non-Small-Cell Lung Cancer | Phase 1 | Recruiting | Second Xiangya Hospital of Central South University | 9 | 2026-06-01 | 2026-10-21 |
| Selective Mediastinal Lymph Node Sampling Versus Systematic medIastinal Lymph Node Dissection After Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cancer (SCIENCE Study) selective mediastinal lymph node sampling, systematic mediastinal lymph node dissection - Stage IIA-IIIB NSCLC, Selective Mediastinal Lymph Node Sampling | Phase 3 | Not yet recruiting | Wen-zhao ZHONG | 358 | 2026-05-20 | 2026-06-01 |
| JS212 Combination Therapies in Metastatic Colorectal Cancer JS212, Capecitabine, Bevacizumab - Metastatic Colorectal Cancer | Phase 2 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 80 | 2026-04-25 | 2026-05-05 |
| Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors JS212 for Injection, JS213 for Injection, JS207 for Injection - Advanced Malignant Solid Tumors | Phase 2 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 410 | 2026-04-23 | 2026-05-29 |
| JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study JS212 for Injection＋JS111 capsules (AP-L1898) - Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations | Phase 2 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 35 | 2026-04-21 | 2026-07-07 |
| A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma JS212, JS001, 5-FU - Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 280 | 2026-04-13 | 2026-04-22 |
| A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer JS212 for Injection, JS207 for Injection, Toripalimab - Advanced Lung Cancer | Phase 2 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 864 | 2026-01-23 | 2026-05-18 |
| JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma. JS107 for Injection, Irinotecan, Paclitaxel - Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 560 | 2025-12-24 | 2026-01-22 |
| JS207 Combination Therapy in Triple-negative Breast Cancer JS207 in combination with 9MW2821, JS207 in combination with Albumin paclitaxel - Triple-negative Breast Cancer | Phase 2 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 80 | 2025-09-17 | 2026-04-15 |
| Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial Ongericimab + Toripalimab + Bevacizumab + FOLFOX, Ongericimab + Toripalimab + Bevacizumab + FOLFIRI - Advanced Colorectal Cancer | Phase 2 | Recruiting | Shanghai Pudong Hospital | 32 | 2025-08-31 | 2026-07-07 |
| JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma JS203 in combination with gemcitabine and oxaliplatin, JS203 in combination with ifosfamide, carboplatin and etoposide, JS203 in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone - B-cell Non-Hodgkin's Lymphoma | Phase 2 | Active not recruiting | Shanghai Junshi Bioscience Co., Ltd. | 180 | 2025-08-17 | 2026-09-04 |
| Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy JS207 injection +docetaxel, JS207 injection +JS004 injection, JS207 injection - Advanced NSCLC | Phase 2 | Terminated | Shanghai Junshi Bioscience Co., Ltd. | 18 | 2025-07-15 | 2026-09-25 |
| JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study JS014 Combined With Toripalimab and TACE - Hepatocellular Carcinoma (HCC) | Phase 1 | Enrolling by invitation | Xiangya Hospital of Central South University | 20 | 2025-07-10 | 2025-09-19 |
| JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC JS207, Pemetrexed injection, Platinum - Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | Shanghai Junshi Bioscience Co., Ltd. | 69 | 2025-06-19 | 2026-08-04 |
| JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma JS207, JS007 - Hepatocellular Carcinoma | Phase 2 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 72 | 2025-05-29 | 2025-07-02 |
| JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC Paclitaxel + Carboplatin/cisplatin for squamous cell carcinoma and pemetrexed + carboplatin/cisplatin for non-squamous cell carcinoma, surgery, Radiochemotherapy - NSCLC | Phase 2 | Active not recruiting | Shanghai Junshi Bioscience Co., Ltd. | 78 | 2025-05-20 | 2026-07-27 |
Showing 20 of 141. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (12) · Carcinoma, Hepatocellular (8) · Melanoma (8) · COVID-19 (6) · Colorectal Neoplasms (6) · Hyperlipidemias (5) · Lymphoma (5) · Nasopharyngeal Carcinoma (5) · Neoplasm Metastasis (5) · Esophageal Squamous Cell Carcinoma (4) · Stomach Neoplasms (4) · Triple Negative Breast Neoplasms (4) · Neoplasms (3) · Recurrence (3) · Biliary Tract Neoplasms (2)
toripalimab (53) · Cisplatin (11) · Injections (11) · Oxaliplatin (10) · Carboplatin (9) · Paclitaxel (9) · Pemetrexed (9) · Bevacizumab (8) · Capecitabine (8) · Gemcitabine (8) · etesevimab (6) · Drug Therapy (5) · lenvatinib (5) · Docetaxel (3) · Fluorouracil (3)
China (128) · United States (7) · Singapore (3) · Taiwan (3) · Argentina (1) · Australia (1) · Georgia (1) · Italy (1) · Netherlands (1) · Poland (1) · Puerto Rico (1) · Spain (1) · Turkey (Türkiye) (1) · Ukraine (1)
Jun Guo (4) · Sheng Yao, PhD (3) · Haitao Zhao, MD (2) · Rui-hua Xu, PhD (2) · Ruihua Xu, MD, PhD (2) · Weihua Wang, Doctor (2) · Chen Ming, MD (1) · Dehua Wu, MD (1) · Fan Yanf, M.D. (1) · Guoxin Li, M.D., Ph.D. (1) · Haitao Haitao, Prof (1) · Haiyan Li, PhD (1) · Huji Xu, PhD (1) · Jia Fan, Ph.D. (1)
PMID 34473343, PMID 30642373, PMID 34374951, PMID 35713300, PMID 33492986, PMID 11251976, PMID 11574279, PMID 14525967, PMID 16682732, PMID 19188168, PMID 20375404, PMID 23749461, PMID 23981851, PMID 24769639, PMID 24852116, PMID 25197551, PMID 25213161, PMID 25409260, PMID 25689070, PMID 25858804, PMID 25981818, PMID 26095784, PMID 26179201, PMID 26598942, PMID 26755520, PMID 26808342, PMID 26959385, PMID 27095655, PMID 27157491, PMID 27234522, PMID 27645897, PMID 27776843, PMID 27806234, PMID 28011330, PMID 28434648, PMID 28818953, PMID 28837405, PMID 29069302, PMID 29341833, PMID 29433850, PMID 29439857, PMID 29543932, PMID 29584545, PMID 29860482, PMID 29882997, PMID 30082870, PMID 30207593, PMID 30213452, PMID 30470260, PMID 30515783